APA

Colson P. H., Virsolvy A., Gaudard P., Charrabi A., Corbani M., Manière M. J., Richard S. & Guillon G. (20171220). Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile. : Pharmacological research.

Chicago

Colson Pascal H, Virsolvy Anne, Gaudard Philippe, Charrabi Azzouz, Corbani Maithé, Manière Maxime J, Richard Sylvain and Guillon Gilles. 20171220. Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile. : Pharmacological research.

Harvard

Colson P. H., Virsolvy A., Gaudard P., Charrabi A., Corbani M., Manière M. J., Richard S. and Guillon G. (20171220). Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile. : Pharmacological research.

MLA

Colson Pascal H, Virsolvy Anne, Gaudard Philippe, Charrabi Azzouz, Corbani Maithé, Manière Maxime J, Richard Sylvain and Guillon Gilles. Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile. : Pharmacological research. 20171220.